摘要
目的探讨MAGE-A3在非小细胞肺癌(non-small cell lung cancer,NSCLC)患者胸腔积液中的表达与临床疗效的关系,为个体化治疗提供指导。方法回顾性分析62例NSCLC(48例肺腺癌、14例鳞癌)患者胸腔积液中MAGE-A3和Ki-67抗原表达水平,比较其与临床疗效的相关性。结果 MAGE-A3、Ki-67在NSCLC患者胸腔积液的表达水平与临床疗效呈负相关,且两者表达水平呈正相关(均P<0.05)。其中,胸腔积液MAGE-A3表达阳性患者较表达阴性者临床疗效差(P<0.05)。MAGE-A3表达水平与年龄、性别、胸腔积液量、癌症类型、KPS评分无相关性(P>0.05)。结论 MAGE-A3表达可能在NSCLC侵袭转移中发挥重要作用,为胸腔积液疗效评估及个体化治疗策略制定提供依据。
Objective To investigate the relationship between MAGE-A3 level in pleural effusion and the therapeutic efficacy of non-small cell lung cancer（NSCLC）. Methods The levels of MAGE-A3 and Ki-67 in pleural effusion were measured in 62 NSCLC cases,including 48 cases of lung adenocarcinoma and 14 of squamous cell carcinoma. The correlation of MAGE-A3 level with clinical efficacy was analyzed. Results The levels of MAGE-A3 and Ki-67 in pleural effusion were positively correlated （ P 〈 0.05 ） , while the levels were negatively correlated with the clinical outcomes （ both P 〈 0.05 ）. However, MAGE-A3 level was not correlated with age, sex, amount of pleural effusion, type of carcinoma, and KPS score in patients （ all P 〉 0.05 ）. Conclusion MAGE-A3 level in pleural effusion may be used as an indicator for prognosis in NSCLC.
出处
《实用肿瘤杂志》
CAS
2013年第2期155-158,共4页
Journal of Practical Oncology
基金
安徽省高校省级科技创新团队计划项目
省级自然科学研究项目(2006KJ100C)
关键词
黑色素瘤
免疫学
抗原
肿瘤
代谢
基因表达
癌
非小细胞肺
病理学
胸腔积液
病理学
KI-67抗原
代谢
回顾性研究
melanoma/immunology
antigens, neoplasm/metabolism
gene expression
carcinoma, non-small-cell lung/ pathology
pleural effusion/pathology
Ki-67 antigen/metabolism
retrospective studies
